You are here

Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis

Last updated on December 6, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ankylosing Spondylitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Proven diagnosis of Ankylosing Spondylitisin accordance with local guidelines

- Patients treated as an outpatient

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who suffer from hypersensitivity to the active substance Etanercept or to any
of the excipients of Enbrel®.

- Treatment with Enbrel® should not be initiated in patients with active infections
including chronic or localised infections.

- Patients with sepsis or risk of sepsis should not be treated.

NCT01188655
Pfizer
Completed
Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Ankylosing Spondylitis
NCT00420238
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis
NCT00751387
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis
NCT00900796
All Genders
18+
Years
Madrid,
Ankylosing Spondylitis
NCT03502616
All Genders
18+
Years
Multiple Sites
Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
Observational Non-Interventional Study With Enbrel in Patients With Ankylosing Spondylitis
This observational study will be a documentation of the prescribing and administration practices of Enbrel® and their impact on ankylosing spondylitis patients outcome in a real life setting.
The study population will be described using standard descriptive statistics for demographic, clinical, medical, characteristics, as well as for standard health-related quality of life and functional disability questionnaires .
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
The patient cohort in this non-interventional study will reflect the kind of patients seen in routine clinical practice and will not be specifically pre-selected as it is the case in clinical studies.
Spondylitis, Ankylosing
Drug: Enbrel

The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits.

Other Name: etanercept
Treatment Group Enbrel
Intervention: Drug: Enbrel
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
89
March 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Proven diagnosis of Ankylosing Spondylitisin accordance with local guidelines
  • Patients treated as an outpatient

Exclusion Criteria:

  • Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel®.
  • Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localised infections.
  • Patients with sepsis or risk of sepsis should not be treated.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01188655
0881X1-4456
B1801095
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now